Table 1.
Characteristics
| Patient/tumor no | Age | Sex | PS | History of cancer | Site of tumor | Histology | Previous treatment | Stage | Tumor size long/short/depth (mm) volume (mm3) |
No. of seed | Result |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1/1 | 84 | M | 0 |
Lung ca Laryngeal ca |
Nose | Basal cell carcinoma | RT: Electron 65 Gy | r2 |
22/21/8 1920 |
83 | PR |
| 2/2 | 62 | M | 0 |
Esophageal ca Gastric ca |
Soft palate | SCC |
Anticancer agent RT: X-ray 60 Gy |
r4 |
21/10/3 500 |
13 | CR |
| 3/3 | 66 | M | 0 | None | Head Subcutaneous | Neuroblastoma |
Anticancer agent Surgery RT: X-ray 30 Gy, Electron 30 Gy |
– |
24/18/7 1620 |
28 | SD |
| 4/4 | 82 | F | 0 | None | Buccal mucosa | SCC |
Anticancer agent, RT: Au-BT 67 Gy |
r1 |
20/16/3 753 |
12 | PR |
| 5/5 | 73 | M | 0 |
Lung ca Bladder ca |
Tongue | SCC |
RT: X-ray 30 Gy Cs-BT 60 Gy Au-BT 85 Gy, 77 Gy |
r1 |
10/6/3 141 |
6 | CR |
| 6/6 | 45 | M | 0 | None | Tongue | SCC |
Anticancer agent Surgery RT: Ir-BT 70 Gy Au-BT 162 Gy |
r1 |
12/10/3 319 |
12 | PD |
| 7/7 | 72 | M | 0 | Tongue ca | Tongue | SCC |
Surgery RT: Ir-BT 70 Gy |
r3 |
30/18/3 1271 |
30 | PR |
| 8/8 | 81 | M | 1 | Oropharyngeal ca | Buccal mucosa | SCC |
Anticancer agent RT: X-ray 65 Gy |
r1 |
12/8/4 201 |
11 | PR |
| 9/9 | 76 | M | 1 |
Esophageal ca Prostate ca Gastric ca |
Floor of the mouth | SCC | RT: X-ray 70 Gy | r2 |
25/15/8 1200 |
45 | CR |
| 10/10 | 74 | F | 1 |
Hypopharyngeal ca Esophageal ca |
Lower lip | SCC |
Surgery, RT: X-ray 48 Gy |
r1 |
15/8/5 370 |
20 | PR |
| 10/11 | Same as above | Upper lip | SCC |
Surgery RT: X-ray 48 Gy |
r1 |
20/7/4 320 |
22 | PR | |||
PS performance status, ca. cancer, RT radiotherapy, Au-BT brachytherapy using Au-198 grains, Cs-BT brachytherapy using Cs-137 needles, Ir-BT brachytherapy using Ir-192 hair and single pins